You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY Glioblastoma (GBM) is an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomide (TMZ). Efforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brain. In contrast, sensitizing GBM to TMZ is an appealing strategy because TM ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Developing an automated yeast dissection system for aging research

    SBC: Innovative BioChips LLC            Topic: NIA

    PROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. A smartphone-based point-of-care test for detection of Chlamydia trachomatis

    SBC: LUMINOSTICS INC            Topic: NIAID

    ABSTRACT The ultimate goal of this project is CLIP CTan FDA cleared and CE marked smartphone based testminfor Chlamydia trachomatisCTinfections in women in over the counterOTCand point of carePOCsettingsCT is the most common bacterial cause of sexually transmitted infectionswith almostmillion new cases in the US each yearUntreated womenmostly in theage groupare at high risk of serious sequelae inc ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    Recent FDA approvals of ipilimumabnivolumaband pembrolizumabwhich target checkpoint receptors cytotoxic T lymphocyte associated antigenCTLAand programmed deathPDhave ushered in a new era of cancer immunotherapy in metastatic melanomaDespite unprecedented overall survival benefits with combination therapythe incidence of complete responses are onlyimmune related adverse eventsirAEsare increasedand ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors

    SBC: Onconano Medicine, Inc.            Topic: NCI

    Abstract The goal of this project is to develop IV injectable fluorescent agents for use in intraoperative imaging of peritoneal metastatic tumors. Significance: Peritoneal metastatic cancers have an incidence of 250,000/per year in the US and are primarily treated with surgery. Complete surgical tumor resection is a gold-standard treatment goal that can increase the 5-year patient survival to 50% ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. sHLA Protein Chip

    SBC: GENOMICS USA, INC.            Topic: NIAID

    Abstract: “sHLA Protein Chip” The class I [A, B, C] and class II HLA proteins [DRB1, DQ, DP] comprise the heart of the inducible human immune system. For organ, marrow and stem cell transplantation, the development of serum-born antibodies against one or more of those many HLA proteins comprises the best and earliest test for transplant rejection. Because of the enormous medical importance of ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A cloud-based system for scalable, privacy-preserving, and interactive immune repertoire analysis in vaccination and infection

    SBC: ImmuDX LLC            Topic: NIAID

    PROJECT SUMMARY We propose to build a cloud based integrated solution for scalablecustomizableprivacy preservingand interactive antibody repertoire analysisImmune repertoire sequencingIR seqhas become a useful tool in both basic research and clinical settingsAs the heart of the adaptive immunity to infection and many vaccinesthe abundance and diversity composition of the B cell receptorBCRand its ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. An Inhaled Clofazimine Formulation for the Treatment of Tuberculosis

    SBC: LYNNTECH INC.            Topic: NIAID

    PROJECT SUMMARY According to the World Health Organizationabout one third of the world s population is infected with Mycobacterium tuberculosisMtband as many asof infected individuals will develop active tuberculosisTBat some point after infectionTB is a curable diseaseyet it still has a high mortality rateinmillion people died from the diseaseThe global control of TB is complicated due to the hig ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government